MobiHealth News April 24, 2024
Xaira’s CEO, Dr. Marc Tessier-Lavigne, resigned as president of Stanford University last August due to controversy over inaccuracies discovered in his lab’s scientific papers.
Xaira Therapeutics, an AI-enabled drug discovery and development company, announced its launch with more than $1 billion in capital.
The biotechnology company is a joint incubation by ARCH Venture Partners and Foresite Labs, the lead investors in the funding round.
Lux Capital, Two Sigma Ventures, F-Prime, Rsquared, SV Angel, Menlo Ventures, Sequoia Capital, NEA, the Parker Institute for Cancer Immunotherapy (PICI), Byers Capital, and Lightspeed Venture Partners also participated in the round.
WHAT IT DOES
Xaira uses machine learning research, data generation models and therapeutic product development to create an AI-enabled platform for...
Today's Sponsors
Today's Sponsor